Development and validation of an epigenetic signature of allostatic load.

Abstract

The allostatic load (AL) concept measures physiological dysregulation in response to internal and external stressors that accumulate across the life course. AL has been consistently linked to chronic disease risk across studies. However, there is considerable variation in its operationalization. In the present study, DNA methylation (DNAm) data (using the Illumina Infinium MethylationEPIC BeadChip (EPIC) array) from the Swiss Kidney Project on Genes in Hypertension (SKIPOGH) cohort, a Swiss-based family cohort study, were used in a discovery epigenome-wide association study (EWAS) to identify CpG sites associated with phenotypic measures of AL. Elastic net linear regression models were used to estimate an epigenetic signature of AL (methAL), including an Illumina HumanMethylation450K (HM450K) assay-compatible signature (methALT). The methALT signature was validated in the 1936 Lothian Birth Cohort (LBC1936), population-based prospective cohort study. We found that the methAL signature was positively associated with the clinical phenotype of AL in both the SKIPOGH (R2= 0.59) and LBC1936 (R2=0.16) cohorts. In the validation cohort, a one SD increase in methALT signature was associated with 25% higher odds of reported history of CVD (OR=1.25, 95% CI=1.05-1.50), and a nearly two-fold increase in all-cause mortality rate at the beginning of follow-up (HR= 1.68, 95% CI= 1.33-2.13) when adjusting for all potential confounders. In conclusion, the epigenetic signature for AL not only correlated well with phenotype-based AL scores, but also exhibited a stronger association with history of CVD and all-cause mortality compared to AL scores. The methAL signature could help assuage issues of comparison across studies.